Christine Leopold1, Anita K Wagner2, Fang Zhang2, Christine Y Lu2, Craig C Earle3, Larissa Nekhlyudov2,4, Dennis Ross-Degnan2, J Frank Wharam2. 1. Department of Population Medicine, Division of Health Policy and Insurance Research, Harvard Medical School and Harvard Pilgrim Health Care Institute, Landmark Center, 401 Park Drive Suite 401, Boston, MA, 02215, USA. christine_leopold1@hphc.org. 2. Department of Population Medicine, Division of Health Policy and Insurance Research, Harvard Medical School and Harvard Pilgrim Health Care Institute, Landmark Center, 401 Park Drive Suite 401, Boston, MA, 02215, USA. 3. Ontario Institute for Cancer Research, Ontario, Canada. 4. Department of Medicine, Brigham & Women's Hospital, Boston, MA, USA.
Abstract
PURPOSE: High-deductible health plan (HDHP) enrollment is expanding rapidly and might substantially increase out-of-pocket (OOP) payment burden. We examined trends in total and OOP health service expenditures overall and by insurance coverage type among women with metastatic breast cancer. METHODS: We used a longitudinal time series design to examine measures among 5364 women with metastatic breast cancer insured by a large US health insurer from 2004 to 2011. We measured outcomes during the 12 months after a first identified metastatic breast cancer diagnosis and required women to have at least 6 months of prior enrollment. We plotted enrollment measures and adjusted total and OOP spending. We fit trend lines using linear autoregressive models. RESULTS: Between 2004 and 2011, the percentage of women with metastatic breast cancer enrolled in employer-mandated HDHPs increased from 8 to 23% while the percentage enrolled in employer-mandated low-deductible plans (LDHPs) decreased from 69 to 37%. Over the same time period, estimated annual inflation-adjusted total health service spending among women with metastatic breast cancer whose employers only offered HDHPs or LDHPS increased from $96,899 to $104,688 (increase of $1197 per year; 95% confidence interval [CI]: $47,$2,348). Corresponding OOP spending values among these women with employer-mandated deductible levels were $4,496 and $5,151 ($91 per year trend; 95% CI -$13,$195). From 2004-2011, women in HDHPs and LDHPs had unchanged annual OOP spending, estimated at of $6642 (95% CI $6,268,$7016) and $4,247 (95% CI $3956,$4538), respectively. Thus, women in HDHPs experienced 55% (44%, 66%) more OOP spending than women in LDHP. CONCLUSIONS: OOP spending among women with metastatic breast cancer and employer-mandated deductible levels was 55% higher among HDHP than LDHP members, and employer-mandated HDHP enrollment increased substantially from 2004 to 2011. Stakeholders and policymakers should design health plans that protect financially vulnerable cancer patients from high OOP costs.
PURPOSE: High-deductible health plan (HDHP) enrollment is expanding rapidly and might substantially increase out-of-pocket (OOP) payment burden. We examined trends in total and OOP health service expenditures overall and by insurance coverage type among women with metastatic breast cancer. METHODS: We used a longitudinal time series design to examine measures among 5364 women with metastatic breast cancer insured by a large US health insurer from 2004 to 2011. We measured outcomes during the 12 months after a first identified metastatic breast cancer diagnosis and required women to have at least 6 months of prior enrollment. We plotted enrollment measures and adjusted total and OOP spending. We fit trend lines using linear autoregressive models. RESULTS: Between 2004 and 2011, the percentage of women with metastatic breast cancer enrolled in employer-mandated HDHPs increased from 8 to 23% while the percentage enrolled in employer-mandated low-deductible plans (LDHPs) decreased from 69 to 37%. Over the same time period, estimated annual inflation-adjusted total health service spending among women with metastatic breast cancer whose employers only offered HDHPs or LDHPS increased from $96,899 to $104,688 (increase of $1197 per year; 95% confidence interval [CI]: $47,$2,348). Corresponding OOP spending values among these women with employer-mandated deductible levels were $4,496 and $5,151 ($91 per year trend; 95% CI -$13,$195). From 2004-2011, women in HDHPs and LDHPs had unchanged annual OOP spending, estimated at of $6642 (95% CI $6,268,$7016) and $4,247 (95% CI $3956,$4538), respectively. Thus, women in HDHPs experienced 55% (44%, 66%) more OOP spending than women in LDHP. CONCLUSIONS: OOP spending among women with metastatic breast cancer and employer-mandated deductible levels was 55% higher among HDHP than LDHP members, and employer-mandated HDHP enrollment increased substantially from 2004 to 2011. Stakeholders and policymakers should design health plans that protect financially vulnerable cancerpatients from high OOP costs.
Entities:
Keywords:
Affordability; High-deductible health plans; Insurance coverage; Metastatic breast cancer; Out-of-pocket spending
Authors: S Yousuf Zafar; Jeffrey M Peppercorn; Deborah Schrag; Donald H Taylor; Amy M Goetzinger; Xiaoyin Zhong; Amy P Abernethy Journal: Oncologist Date: 2013-02-26
Authors: Nancy Krieger; Jarvis T Chen; Pamela D Waterman; David H Rehkopf; S V Subramanian Journal: Am J Public Health Date: 2003-10 Impact factor: 9.308
Authors: Nicole Meyer; Yanni Hao; Xue Song; Nianwen Shi; William Johnson; Jaqueline Willemann Rogerio; Denise A Yardley Journal: Int J Breast Cancer Date: 2014-08-07
Authors: Ya-Chen Tina Shih; Ying Xu; Cathy Bradley; Sharon H Giordano; James Yao; K Robin Yabroff Journal: J Natl Cancer Inst Date: 2022-10-06 Impact factor: 11.816
Authors: Karen J Wernli; Katherine A Callaway; Louise M Henderson; Karla Kerlikowske; Janie M Lee; Dennis Ross-Degnan; Jamie K Wallace; J Frank Wharam; Fang Zhang; Natasha K Stout Journal: Cancer Date: 2020-09-28 Impact factor: 6.860
Authors: Wenqi Fu; Jufang Shi; Xin Zhang; Chengcheng Liu; Chengyao Sun; Yupeng Du; Hong Wang; Chaojie Liu; Li Lan; Min Zhao; Li Yang; Burenbatu Bao; Sumei Cao; Yongzhen Zhang; DeBin Wang; Ni Li; Wanqing Chen; Min Dai; Guoxiang Liu; Jie He Journal: BMJ Open Date: 2021-06-30 Impact factor: 2.692